Abstract The financial burden for EU health systems associated with cardiovascular disease (CV) has been estimated to be nearly €110 billion in 2006, corresponding to 10 % of total healthcare expenditure across EU or a mean €223 annual cost per capita. The main purpose of this study is to estimate the costs related to hypertension and the economic impact of increasing adherence to anti-hypertensive therapy in five European countries (Italy, Germany, France, Spain and England). A probabilistic prevalence-based decision tree model was developed to estimate the direct costs of CV related to hypertension (CV defined as: stroke, heart attack, heart failure) in five European countries. Our model considered adherence to hypertension treatment as a main driver of blood pressure (BP) control (BP \ 140/ 90 mmHg). Relative risk of CV, based on controlled or uncontrolled BP group, was estimated from the Framingham Heart Study and national review data. Prevalence and cost data were estimated from national literature reviews. A national payer (NP) perspective for 10 years was considered. Probabilistic sensitivity analysis was performed in order to evaluate uncertainty around the results (given as 95 % confidence intervals). The model estimated a total of 8.6 million (1.4 in Italy, 3.3 in Germany, 1.2 in Spain, 1.8 in France and 0.9 in England) CV events related to hypertension over the 10-year time horizon. Increasing the adherence rate to antihypertensive therapy to 70 % (baseline value is different for each country) would lead to 82,235 fewer CV events (24, 058 in Italy, 7, 870 in Germany, 18, 870 in Spain, 24, 855 in France and 6,553 in England). From the NP perspective, the direct cost associated with hypertension was estimated to be €51.3
Introduction
Safe and effective treatments for a range of health issues are widely available in Europe. These treatments, however, are not always used to their full potential. They can be limited by many factors, including a lack of adherence to treatment. The reasons behind low adherence are complex, and can include a variety of factors (such as socio-economic status, patient beliefs and lifestyle, health-literacy) and their interaction with the health care system.
Better adherence to medical treatment, as well as medical and prevention plans, will improve the quality of life of patients and help support the long-term sustainability of health care systems [1] .
In Europe, about 4.58 million people die every year due to cardiovascular diseases (CV) [2] . In the 25 European countries, the annual expenditure for the treatment of CVs is estimated to be about €169 billion [3] . Of this, about 61 % is attributable to direct healthcare costs.
The treatment of hypertension, one of the main risk factors, reduces the number of adverse cardiovascular events and thus decreases the economic and health impact of hypertension related CV [4] [5] [6] . The effectiveness of therapies used to treat hypertension has been shown to be closely related to the patients' medical adherence to treatment [7, 8] . A level of good adherence needed for a pharmacological treatment to be effective is widely recognized to be around 80 % of the prescribed therapy [9] . Existing research shows that in several European countries \60 % of treated hypertensive subjects have an adherence to their treatment over 80 % [10] [11] [12] [13] [14] . Poor adherence results in severe losses in terms of clinical efficacy and economic efficiency, especially as the cardiovascular events that full adherence could avoid translate into greater hospitalisation costs.
Non-adherence to anti-hypertensive drugs remains a global issue and one of the main clinical obstacles to the reduction of cardiovascular morbidity and mortality. One study [15] has estimated that in the United States 100 % adherence to treatment could reduce the risk of CV by 32 %, with 8.5 million fewer events over 10 years followup and cumulative savings to the health care system of $72 billion [15] . To date this is the only systematic analysis published, but its results cannot be transferred directly to Europe, since there exist considerable variations in healthcare systems both between the United States and Europe, and between different European countries. The main purpose of this study is therefore to estimate the total cost of CV related to hypertension and the economic impact of non-adherence to medical anti-hypertensive therapy in five European countries (England, France, Germany, Italy and Spain).
Methods

Model
A prevalence based probabilistic model was developed to estimate the costs and consequences of CV, using risk equations to estimate the risk of cardiovascular events based on the Framingham Heart Study. The model simulates the natural history of the disease, where patients residing in each of the countries included in the analysis may or may not be hypertensive (Fig. 1) . Hypertensive patients (BP C 140/90) may or may not be diagnosed with hypertension. The model assumes that all diagnosed patients are treated and that adherence to treatment (defined as the extent to which a patient acts in accordance with the prescribed interval and dose of a dosing regimen [16] ) is the main driver for the patient to achieve a controlled blood pressure (BP \ 140/90) and consequently a lower probability of experiencing a cardiovascular event.
The model assumes that all undiagnosed hypertensive patients have an uncontrolled BP while the non-hypertensive subjects maintain a BP \ 140/90. On the basis of the Framingham [17] risk equations, all subjects, including those who are not hypertensive, have a defined probability of experiencing a CV event.
The model is used to produce a risk estimate over a 10-year period. Costs are estimated from a health system perspective using demographic, epidemiological and economic data obtained from national and international literature for each country included in the analysis.
Cardiovascular disease (CV) event
The cardiovascular risk equation reported by D'Agostino et al. [17] produces estimates of the risk of CV which varies depending on the patient's age and other demographic characteristics, on clinical parameters including BP and on other risk factors. In our model, the population has been divided into four risk groups: diagnosed subjects with controlled BP (BP \ 140/90) after treatment, diagnosed subjects with uncontrolled BP (BP C 140/90) after treatment, hypertensive but undiagnosed subjects (BP C 140/ 90) and healthy subjects (BP \ 140/90). Within each risk group, the composition by age of the population of each country included in the analysis (Appendix A) was considered.
The sum of cardiovascular risk scores, by BP risk group and age-weighted, produced the 10-year CV event probabilities shown in Table 1 .
In order to estimate the costs of CV events attributable to hypertension, we considered a percentage of CV events that was assumed (by literature review) related to hypertension (Appendix B table B-1) [15] . As the focus of this study relates to costs of hypertension and non-adherence to therapy, healthy subjects were not considered in our cost analysis.
Demographic and epidemiological data
Demographic and epidemiological parameter values for each country are included in the analysis, and information about the prevalence of diagnosed and undiagnosed to hypertension and treatment adherence were obtained from national and international literature: values and sources are reported in Table 2 .
Estimate of direct healthcare costs
In accordance with the perspective of the analysis, only direct healthcare costs associated with the treatment and control of hypertension and all related CV events were Table 3 . Medical costs of cardiovascular events were assessed as a weighted average depending on country-specific number of events attributable to hypertension and associated hospitalisation rates (Appendix B).
Scenarios and sensitivity analyses
The impact of improving adherence was compared against the current values for each country as reported in Table 2 . In the main scenario, it was assumed that the number of subjects treated, and having an adherence rate to antihypertensive treatment equal or above 80 %, would increased to 70 % in all countries. The model was run at current adherence levels and at 70 % of treated subjects, in order to estimate the difference in CV events and related costs under the two scenarios.
Probabilistic sensitivity analysis (PSA) was also carried out through Monte Carlo simulations based on a range of probabilities for each parameter considered in the model (Appendix C). Sensitivity analysis enabled the estimation of 95 % confidence intervals (CI 95 %) around the mean value, using the percentile method to identify the upper and lower 95 % bounds over 5,000 simulations. The model and the sensitivity analysis were developed in Microsoft Excel Ò (Microsoft, Redmond, WA, USA).
Results Table 4 reports the predicted number and cost of all CV events related to hypertension for each country and aggregated across all five countries. Over the 10-year time horizon, a total of almost 8.6 million CV events are predicted based on current demographic, epidemiological and adherence data (32 % were estimated to occur in Germany, 20 % in France and Italy, and 15 and 12 % in Spain and England, respectively). The total cost of CV events attributable to hypertension was estimated to exceed €51.3 [18] 81,843,743 [19] 46,815,916 [20] 65,281,000 [21] 52,642,500 [22] Percentage of females 51.48 % [18] 50.87 % [19] 50.65 % [20] 51.57 % [21] 50.84 % [22] Percentage of females;
age C 30 years 71.76 % [18] 70.86 % [19] 69.37 % [20] 64.76 % [21] 63.54 % [22] Percentage of males; Percentage of diagnosed and treated hypertensive subjects 73.00 % [30] 77.00 % [31] 59.40 % [26] 56.92 % [27, 29] 58.38 % [32] Percentage of diagnosed patients with adherence C80 % 41.50 % [9] 66.90 % [13] 39.40 % [14] 39.00 % [12] 56.85 % [11] billion over a time span of 10 years (range €5.0 in England and €17.1 in Germany). Considering only the costs associated with diagnosed and treated patients, drug cost is estimated, on average, to represent 37 % (range 10 % in England and 71 % in Spain) of the total cost of the disease and the remaining part being attributed to hospitalisations (Table 5 ). In Italy, a total cost related to diagnosed and treated hypertensive patients of €6.4 billion (CI 95 %: €5.5-7.2 billion) was estimated over a 10 years horizon. Similarly, in France, the cost associated with hospitalisation was estimated at €3.3 billion (CI 95 %: €3.0-3.7 billion) and the total expenditure for diagnosed subjects amounted to €5.7 billion (CI 95 %: €4.9-6.5 billion).
Total costs related to diagnosed patients were much higher in Germany and Spain than in other countries. In Germany, where the prevalence of hypertension (Table 2) and of diagnosed subjects (Table 4) were both high, total expenditure was estimated to be €13.8 billion (CI 95 %: €11.9-15.7 billion). In Spain, the high cost associated with hypertensive patients was attributable to a total drug cost of €7.0 billion (CI 95 %: €6.3-7.8 billion), higher than any other country and approximately three times the cost of hospitalisations (€2.8 billion, CI 95 %: €2.5-3.2 billion).
In England, drug costs of just €0.2 billion (CI 95 %: €0.2-0.3 billion) were particularly low, corresponding to 4.7 % of the total expenditure related to hypertensive treatment and hospitalisation cost. These lower drug costs reflect a high proportion of generic drugs in the total drugs used, and low generic prices in the UK.
Finally, the study estimated that, by increasing to 70 % the adherence to treatment in all countries, it would be possible to reduce direct healthcare costs for hypertension by about €332 million (CI 95 %:-€319 to -346) (Appendix D, Table D. 3) equal to 82,235 fewer CV events (24,058 in Italy, 7,870 in Germany, 18,870 in Spain, 24,855 in France and 6,553 in England) (see supplementary Appendix E).
By looking at savings at national level (Fig. 2) , it can be seen that countries are clustered into two groups. In the first, cost reductions due to increased adherence are in the order of €26-36 million (Germany and England); in the second group there is a substantially higher impact of increased adherence, with cost reductions exceeding €80 million (Italy, Spain and France). The reasons for the lower level of cost reduction in the first group differ between the two countries: Germany (average savings €26.7 million, CI 95 %: -€32.4 to -€21.0) is characterised by adherence to treatment at the baseline (66.9 %) which is already very close to the target value of 70 %, whereas in England (average savings €36.1 million CI 95 %: -€30.8 to 41.5) the cost of drugs is significantly lower than the European average, and therefore savings are mainly attributable to hospitalisation cost.
In the second group, the quite low adherence (range 39.0-41.5 %) and the non-negligible costs of drugs and hospitalisation determine level of savings higher than €80 million for each of the three counties: Italy (€95.0 million, CI 95 %: -€91.5 to -€98.4), Spain (€80.9 million, CI Cost of poor adherence to anti-hypertensive therapy 69
95 %: -€73.3 to -€88.5) and France (€93.6 million, CI 95 %: -€91.0 to -€96.2).
Discussion and conclusion
This is the first study which aims to estimate costs associated with non-adherence to anti-hypertensive treatment in five European countries. A recent study reported that, comparing current adherence rates of approximately 40 % with hypothetical full adherence of 100 %, non-adherence can be estimated to entail a clinical and financial burden of over 8.5 million CV events and about $ 72 billion in the USA [15] over 10 years. Our analysis assumed a more realistic scenario, in which adherence levels in the five European countries could be increased from current levels to 70 % of treated patients: in other words, a scenario where 70 % of patients prescribed for an antihypertensive treatment take at least 80 % of their given regimen. Our analysis indicates that this would reduce CV-related health care costs by €332 million (CI 95 %: -€319 to -€345) over a 10-year period. A study by Leal et al. [3] estimated the annual economic impact of CV through the main national sources of epidemiological and financial data. In line with our results over the course of 10 years, Leal et al. estimated an annual average expenditure of €16.1 billion (2003) for the five countries included in our analysis (drug, primary, outpatient, emergency, and inpatient care) or €14.7 billion (2003) for outpatient and hospitalisation costs only. If onethird of the total events estimated by Leal et al. are assumed to be associated with hypertension [17] , the total cost per year would be €4.8 billion per year, close to the €5.1 billion (CI 95 % €4.7-5.5 billion) per year estimated in our study.
The present study has some limitations, mostly attributable to assumptions and estimates which were necessary to overcome the lack of standardised data for the five countries of interest. Our epidemiological data were either obtained from statistics provided by national institutions or extrapolated estimates from scientific literature. Our estimates for adherence rates were taken from a number of different studies which could have used definitions different to that given in our study [16] . Likewise, costs were obtained from a number of data sources using methods and definitions which may have varied from one country to the other. This applies to both drug costs and hospital costs, which were not completely consistently derived across countries. However, use of PSA has allowed us to capture and explore the variability in the main parameters of the model.
The estimation of risk and of the number of CV events related to hypertension was based on a well-known cohort study-the Framingham Heart Study-that consists of a non-European population, [15, 17] and no adjustments were made for ethnic composition in each country. This limitation could overestimate the risk for some countries as it was illustrated for Germany [45] . However, calculations were adjusted for the age and sex structure of each population, and a 2008 study [46] reported a high correlation between the cardiovascular risks estimated in the Framingham study and those observed in a population of European subjects (SCORE [47, 48] ). Indeed, the Framingham risk equations predict the risk of developing a first CV event and no assumption were considered in our analysis because of no data available.
In conclusion, our study represents the first attempt in Europe to estimate the costs associated with non-adherence to anti-hypertensive treatment, using a probabilistic prevalence based model in five European countries. Despite its limitations, this analysis should help decision makers to better understand the clinical and economic importance of improving adherence at national level, and will help inform strategies to improve adherence to therapy as one key issue of antihypertensive medical therapy. All actions taken to increase patient adherence to anti-hypertensive therapies, such as psychological support to enhance patient's motivation, patient's reminders, and use of fixed dose combination therapies to decrease pill burden, should be assessed by policy makers and healthcare budget holders within a framework that considers not only the short-term costs of these interventions, but also possible offsetting costs due to fewer hospitalisations and improvements in healthcare status.
